NEW YORK, May 11, 2009 — The Bank of New York Mellon, the global leader in asset management and securities servicing, has been selected by Intercell AG ("Intercell") as depositary bank for its sponsored American depositary receipt (ADR) program. Each Intercell ADR represents one ordinary share. The ADRs trade on the over-the-counter market under the symbol "INRLY," and the ordinary shares trade in the Prime Market on the Vienna Stock Exchange under the symbol "ICLL."

Intercell AG, founded as a spin-off from Vienna University in 1998, is a biotechnology company that develops vaccines for the prevention and treatment of infectious diseases. The company operates in three countries with headquarters in Vienna, manufacturing facilities in Scotland, and R&D and production facilities in the U.S. Intercell's first product on the market is a Japanese encephalitis vaccine, which has been approved in the U.S. by the FDA, in Australia by the TGA, and by the European Commission in Europe.

"By offering investors an option to trade Intercell ADRs, we are looking to expand our investor base and increase our visibility in the U.S.," said Dr. Reinhard Kandera, newly appointed CFO of Intercell. "We are convinced that The Bank of New York Mellon will help us achieve these goals as the leading depositary bank with a significant track record working with pharmaceutical and biotech companies."

"We are pleased Intercell has entrusted The Bank of New York Mellon with the establishment of its ADR program and look forward to working closely to facilitate sustained visibility in the U.S. market and to support its U.S.-specific investor relations initiatives," said Michael Cole-Fontayn, chief executive officer of The Bank of New York Mellon's Depositary Receipt Division.

The Bank of New York Mellon acts as depositary for more than 2,100 American and global depositary receipt programs, acting in partnership with leading companies from 67 countries. With an unrivalled commitment to helping securities issuers succeed in the world's rapidly evolving financial markets, the Company delivers the industry's most comprehensive suite of integrated depositary receipt, corporate trust and stock transfer services. Additional information is available at www.bnymellon.com/dr.

The Bank of New York Mellon Corporation is a global financial services company focused on helping clients manage and service their financial assets, operating in 34 countries and serving more than 100 markets. The company is a leading provider of financial services for institutions, corporations and high-net-worth individuals, providing superior asset management and wealth management, asset servicing, issuer services, clearing services and treasury services through a worldwide client-focused team. It has $19.5 trillion in assets under custody and administration, $881 billion in assets under management, services more than $11 trillion in outstanding debt, and processes global payments averaging $1.8 trillion per day. Additional information is available at www.bnymellon.com.

This release is for informational purposes only. The Bank of New York Mellon provides no advice nor recommendation or endorsement with respect to any company or securities. Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy securities. Depositary Receipts: Not FDIC, State or Federal Agency Insured; May Lose Value; No Bank, State or Federal Agency Guarantee.